Recruiting

Observational StudyInvestigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components

Sponsor:

AHS Cancer Control Alberta

Code:

NCT00813787

Conditions

Glioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The purpose of this study is to see if a specialized imaging technique using MRI called multi-exponential T2 component analysis can reliably differentiate between normal brain and brain tumour.

Conditions

Glioma

Study ID

NCT00813787

Start date

Feb, 2009

Status verified date

Oct, 2014

Completion date

Apr, 2015

Anticipated

Primary completion date

Apr, 2015

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

Eighteen years of age or older
Clinical subjects must have not yet begun radiation therapy
Must have signed our study-specific consent form

Exclusion Criteria:

-

Study Design

Enrollment

20 participants

Anticipated

Interventions and Outcome Measures

Arms

A. glioma

A. glioma population

B. Normal brain

Primary outcome measure

T2 characteristics of glioma tissue versus normal [ Time Frame: Before radiotherapy treatment begins ]

Central Contacts and Locations

Central contacts

Keith Wachowicz, PhD

(780) 989-4334 keithwac@cancerboard.ab.ca

Locations

Cross Cancer Institute

Recruiting

Edmonton, Alberta, Canada, T6G 1Z2

More Information

Sponsor

AHS Cancer Control Alberta

Last update posted

Oct 3, 2014

Last verified

Oct, 2014

Keywords

Magnetic Resonance Imaging
Glioma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by AHS Cancer Control Alberta on 2014-10-03.